Abstract
AbstractXeroderma pigmentosum (XP) is a DNA repair disease that predisposes to early skin cancers as cutaneous melanoma. Melanoma microenvironment contains inflammatory mediators, which would be interesting biomarkers for the prognosis or for the identification of novel therapeutic targets. We used a PCR array to evaluate the transcriptional pattern of 84 inflammatory genes in melanoma tumors obtained from XP patients (XP-Mel) and in sporadic melanoma (SP-Mel) compared to healthy skin. Commonly expressed inflammatory genes were further explored via GTEx and GEPIA databases. The differentially expressed inflammatory genes in XP were compared to their expression in skin exposed to UVs, and evaluated on the basis of the overall survival outcomes of patients with melanoma. Monocyte subsets of patients with SP-Mel, XP and healthy donors were also assessed. PCR array data revealed that 34 inflammatory genes were under-expressed in XP-Mel compared to SP-Mel. Differentially expressed genes that were common in XP-Mel and SP-Mel were correlated with the transcriptomic datasets from GEPIA and GTEx and highlighted the implication of KLK1 and IL8 in the tumorigenesis. We showed also that in XP-Mel tumors, there was an overexpression of KLK6 and KLK10 genes, which seems to be associated with a bad survival rate. As for the innate immunity, we observed a decrease of intermediate monocytes in patients with SP-Mel and in XP. We highlight an alteration in the immune response in XP patients. We identified candidate biomarkers involved in the tumorigenesis, and in the survival of patients with melanoma. Intermediate monocyte’s in patients at risk could be a prognostic biomarker for melanoma outcome.
Funder
The Slovenian Research Agency
The "Projet Collaboratif Interne"
Publisher
Springer Science and Business Media LLC
Reference90 articles.
1. Naouali, C. et al. Epidemiological trends and clinicopathological features of cutaneous melanoma in sporadic and xeroderma pigmentosum Tunisian patients. Int. J. Dermatol. 56, 1–40 (2016).
2. Kleijer, W. J. et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair 7, 744–750 (2008).
3. Emmert, S. & Kraemer, K. H. Do not underestimate nucleotide excision repair: It predicts not only melanoma risk but also survival outcome. J. Investig. Dermatol. 133, 1713–1717. https://doi.org/10.1038/jid.2013.72 (2013).
4. Jerbi, M. et al. Clinical, genealogical and molecular investigation of the xeroderma pigmentosum type C complementation group in Tunisia. Br. J. Dermatol. 174, 439–443. https://doi.org/10.1111/bjd.14046 (2016).
5. Friedberg, E. C. How nucleotide excision repair protects against cancer. Nat Rev Cancer 1, 22–33 (2001).